Literature DB >> 17683652

Biology of bone metastases: causes and consequences.

Harold A Harvey1, Leah von Reyn Cream.   

Abstract

Breast cancer is a highly osteotropic neoplasm, and as many as 75% of patients with metastatic disease will have involvement of the bony skeleton. On radiologic examination, these metastases are predominantly osteolytic but can be osteoblastic or mixed. The mechanisms by which metastases are formed are complex, involving many steps that include angiogenesis, invasion, and proliferation in the bone microenvironment. Tumor cells in the bone microenvironment produce a large number of cytokines that stimulate osteoclastic activity. Increased osteoclastic activity, in turn, leads to production of a variety of lymphokines and growth factors that can increase tumor cell proliferation. Thus, a cytokine network is established, which results in an imbalance of the processes of bone formation and bone resorption. As tumor burden in bone increases, osteoclast-mediated bone resorption is accelerated, resulting in loss of bone strength, fractures, pain, and other morbidities. Tumor cells metastatic to bone can also secrete growth factors, leading to increased osteoblastic activity. Osteoblasts lay down an excess of new bone that is structurally weak. There is considerable crosstalk between osteoclasts, osteoblasts, macrophages, and other cellular elements within the bone environment. The increasing understanding of the biology of bone metastases has opened the door to improved management of this important clinical problem. Current treatment strategies include approaches to reduce tumor burden and developing treatments that directly inhibit osteoclast function. The bisphosphonates are a class of drugs that inhibit osteoclast recruitment and function. Several highly potent bisphosphonates are now available for clinical use and represent an important adjunct in the management of bone metastases from breast cancer, multiple myeloma, and several other types of malignancies. Some newer therapeutic approaches include agents designed to inhibit the osteoclast-osteoblast signaling interactions or alter processes of adhesion and invasion.

Entities:  

Mesh:

Year:  2007        PMID: 17683652     DOI: 10.3816/cbc.2007.s.001

Source DB:  PubMed          Journal:  Clin Breast Cancer        ISSN: 1526-8209            Impact factor:   3.225


  14 in total

Review 1.  Abnormal radiological features in a multiple myeloma patient: a case report and radiological review of myelomas.

Authors:  S Ghosh; P Wadhwa; A Kumar; Km Pai; S Seshadri; C Manohar
Journal:  Dentomaxillofac Radiol       Date:  2011-12       Impact factor: 2.419

Review 2.  Role of positron emission tomography for the monitoring of response to therapy in breast cancer.

Authors:  Olivier Humbert; Alexandre Cochet; Bruno Coudert; Alina Berriolo-Riedinger; Salim Kanoun; François Brunotte; Pierre Fumoleau
Journal:  Oncologist       Date:  2015-01-05

3.  Evaluation of antitumor activity and cardiac toxicity of a bone-targeted ph-sensitive liposomal formulation in a bone metastasis tumor model in mice.

Authors:  Diego Dos Santos Ferreira; Bruno Luís Jesus de Oliveira Pinto; Vidhya Kumar; Valbert Nascimento Cardoso; Simone Odília Fernandes; Cristina Maria Souza; Geovanni Dantas Cassali; Anna Moore; David E Sosnovik; Christian T Farrar; Elaine Amaral Leite; Ricardo José Alves; Mônica Cristina de Oliveira; Alexander Ramos Guimarães; Peter Caravan
Journal:  Nanomedicine       Date:  2017-03-23       Impact factor: 5.307

4.  Enhanced anti-tumor activity and safety profile of targeted nano-scaled HPMA copolymer-alendronate-TNP-470 conjugate in the treatment of bone malignances.

Authors:  Ehud Segal; Huaizhong Pan; Liat Benayoun; Pavla Kopečková; Yuval Shaked; Jindřich Kopeček; Ronit Satchi-Fainaro
Journal:  Biomaterials       Date:  2011-03-22       Impact factor: 12.479

5.  Behavioral, medical imaging and histopathological features of a new rat model of bone cancer pain.

Authors:  Louis Doré-Savard; Valérie Otis; Karine Belleville; Myriam Lemire; Mélanie Archambault; Luc Tremblay; Jean-François Beaudoin; Nicolas Beaudet; Roger Lecomte; Martin Lepage; Louis Gendron; Philippe Sarret
Journal:  PLoS One       Date:  2010-10-29       Impact factor: 3.240

6.  Treatment of osteolytic solitary painful osseous metastases with radiofrequency ablation or cryoablation: A retrospective study by propensity analysis.

Authors:  Luigi Zugaro; Mario DI Staso; Giovanni Luca Gravina; Pierluigi Bonfili; Lorenzo Gregori; Pietro Franzese; Francesco Marampon; Vincenzo Tombolini; Ernesto DI Cesare; Carlo Masciocchi
Journal:  Oncol Lett       Date:  2016-01-14       Impact factor: 2.967

7.  Orthopaedic perspective on bone metastasis.

Authors:  Alan P Molloy; Gary C O'Toole
Journal:  World J Orthop       Date:  2013-07-18

Review 8.  Metastatic bone pain: treatment options with an emphasis on bisphosphonates.

Authors:  Roger von Moos; Florian Strasser; Silke Gillessen; Kathrin Zaugg
Journal:  Support Care Cancer       Date:  2008-08-06       Impact factor: 3.603

9.  Treatment of Solitary Painful Osseous Metastases with Radiotherapy, Cryoablation or Combined Therapy: Propensity Matching Analysis in 175 Patients.

Authors:  Mario Di Staso; Giovanni Luca Gravina; Luigi Zugaro; Pierluigi Bonfili; Lorenzo Gregori; Pietro Franzese; Francesco Marampon; Francesca Vittorini; Roberto Moro; Vincenzo Tombolini; Ernesto Di Cesare; Carlo Masciocchi
Journal:  PLoS One       Date:  2015-06-23       Impact factor: 3.240

10.  Bisphosphonates and osteonecrosis of the jaw: a case report.

Authors:  André Borba Reiriz; Patrícia de Moraes De Zorzi; Cristian Patrik Lovat
Journal:  Clinics (Sao Paulo)       Date:  2008-04       Impact factor: 2.365

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.